Join to View Full Profile
Ambulatory ClinicSeattle, WA 98109
Phone+1 206-288-1000
Dr. Whiting is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2001 - 2005- University of WashingtonResidency, Internal Medicine, 1999 - 2001
- University of Washington School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2024 - 2026
WA State Medical License 2001 - 2025
Clinical Trials
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Start of enrollment: 2017 May 01
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Start of enrollment: 2017 Sep 06
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsFirst-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler
Cancer Research Communications. 2024-04-18 - 29 citationsTelaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli
Clinical Cancer Research. 2022-04-14 - 34 citationsA Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.James J. Harding, Melinda L. Telli, Pamela N. Munster, Martin H. Voss, Jeffrey R. Infante
Clinical Cancer Research. 2021-07-20
Press Mentions
Oncology Drugs Fast-Tracked by the FDA in February 2025March 3rd, 2025- Hyatt Hotel Heir Donates $60 Million for UCSF Psychiatric HospitalMay 12th, 2021
- ‘In the Abyss’: Why Bay Area Health Care Experts Fear JanuaryJanuary 3rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
